Core Viewpoint - The announcement details the investment and share transfer activities of Hunan Fangsheng Pharmaceutical Co., Ltd. and its affiliated investment partnership, focusing on the sale of shares in Hunan Kexin Health Industry Group Co., Ltd. and the implications for the company's capital recovery [2][10]. Group 1: Investment and Share Transfer Details - Hunan Kexin has decided to transfer 51% of its shares in Changsha Kexin Tumor Hospital Co., Ltd. to Yinkang Life Science Co., Ltd. for RMB 357 million, with subsequent transfers of 29% and 20% shares planned based on performance commitments [2][6]. - The company has invested RMB 100 million in the affiliated partnership, initially holding a 16.67% stake, which increased to 21.25% after changes in partner contributions [3][4]. - As of the announcement date, the company has recovered RMB 1.5 million of its investment, with RMB 98.5 million still outstanding [3][8]. Group 2: Financial Implications and Recovery Plans - The expected recovery from the share transfer is estimated at RMB 154.68 million, with the first phase of recovery projected to be RMB 87.61 million [6][8]. - The partnership has a commitment from a subordinate partner to cover any investment losses if the recovery does not meet the required amounts [8][10]. - The company plans to negotiate with partners to ensure the recovery of its outstanding investment before the partnership's expiration in January 2026 [9][10].

格隆汇4月7日丨方盛制药(603998.SH)公布，2025年4月7日，同系方盛函告公司，湖南珂信已于日前召 开股东会，决定以3.57亿元向盈康生命出售其下属医院长沙珂信51%的股权，且后续将根据业绩承诺目 标的完成情况，分别转让长沙珂信29%、20%的股权；湖南珂信拟通过回购股权的方式将其出售长沙珂 信股权获得的股权转让款按照其股东会决议的安排向相关股东回购股权，并对其部分非现金资产进行分 配。回购股权款将根据湖南珂信与盈康生命交易长沙珂信的股权节奏分三期进行付款，按照同系方盛持 有的湖南珂信26.0018%股权（含转让予陈历宏先生或其指定关联方尚未支付股权转让价款的16.30%股 权）计算，预计将获得回购款15,468.34万元；如湖南珂信完成转让长沙珂信51%的股权，则对应湖南珂 信将支付至同系方盛的第一期回购款为8,760.55万元。 截至本公告披露日，公司对同系方盛的实缴出资尚有9,850万元未收回，同系方盛函告已确认在收到湖 南珂信股权回购分期款及陈历宏先生或其指定关联方偿还的股权转让款后，将同步支付公司的实缴出资 款，预计收到第一期回购款至多可收回8,760.55万元（不考虑同系方盛扣除相关日常 ...

Investment Rating - The report maintains a "Recommended" rating for the industry, indicating a positive outlook for the sector's fundamentals and expectations for the industry index to outperform the benchmark index [4]. Core Insights - The pharmaceutical industry is primarily driven by domestic demand, with most sub-sectors minimally affected by tariff impacts, such as medical services, innovative domestic drugs, traditional Chinese medicine, and pharmacy/retail [1][3]. - There is significant potential for import substitution in high-import sectors like blood products, certain medical devices, and key components, which are expected to benefit marginally from the current tariff situation [1]. - The report highlights specific sectors to watch, including blood products, domestic consumption-related sectors, and medical devices, which are poised for growth due to favorable policies and market conditions [2]. Summary by Relevant Sections Blood Products - The overseas share of human albumin exceeds 60%, and with tariffs on imported albumin, domestic prices are expected to recover. The "14th Five-Year Plan" for new plasma stations is also promising. Companies to focus on include Palin Biotech, Tiantan Biological, and Boya Biological [2]. Domestic Consumption - External impacts are minimal, and consumption policies are catalyzing recovery in certain areas. Key companies include medical services (e.g., Aier Eye Hospital, Tongce Medical), beauty services (Aimeike), pharmacies (Yifeng Pharmacy, Dazhong Pharmacy), and traditional Chinese medicine (Dong-E E-Jiao, China Resources Sanjiu) [2]. Medical Devices - For core components, the domestic market for medical CT tubes is largely dominated by imports, with potential benefits from anti-dumping investigations. Companies to watch include Yirui Technology and United Imaging Healthcare [2]. - In consumables, the domestic market for electrophysiology is under 10% localization, with U.S. companies leading. Companies like Huitai Medical and Microelectrophysiology are expected to benefit from increased localization [2]. - In vitro diagnostics (IVD) are also highlighted, with certain leading foreign companies facing tariffs that may accelerate import substitution. Recommended companies include New Industries, Mindray Medical, Antu Biology, and Yanhui Long [2]. Pharmaceuticals - The report indicates that the pharmaceutical sector is largely unaffected by tariffs, with a focus on domestic innovation. Companies to monitor include Heng Rui Medicine, Innovent Biologics, and Fuhong Hanlin [3].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

独立董事候选人声明与承诺 本人杜守颖，已充分了解并同意由提名人湖南方盛制药股份 有限公司董事会提名为湖南方盛制药股份有限公司第六届董事 会独立董事候选人。本人公开声明，本人具备独立董事任职资格， 保证不存在任何影响本人担任湖南方盛制药股份有限公司独立 董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明 材料。 （八）中国证监会《证券基金经营机构董事、监事、高级管 理人员及从业人员监督管理办法》等的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校 反腐倡廉建设的意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事 制度指引》等的相关规定（如适用）； （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监 ...

一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 独立董事候选人声明与承诺 本人高学敏，已充分了解并同意由提名人湖南方盛制药股份 有限公司董事会提名为湖南方盛制药股份有限公司第六届董事 会独立董事候选人。本人公开声明，本人具备独立董事任职资格， 保证不存在任何影响本人担任湖南方盛制药股份有限公司独立 董事独立性的关系，具体声明并承诺如下： 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； 反腐倡廉建设的意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事 制度指引》等的相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管 理人员及从业人员监督管理办法》等的相关规定（如适用）； （九）《银行业金融机构董事（理事）和高级管理人员任职 资格管理办法》《保险公司董事、监事和高级管理人员任职资格 管理规定》《保险机构独立董事管理办法》等的相关规定（如适 用）； 本人 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第六号——医药制造》、 《关于做好主板上市公司 2024 年第三季度报告披露工作的重要 提醒》的要求，湖南方盛制药股份有限公司（以下简称"公司"） 现将 2024 年前三季度主要经营数据披露如下： 一、报告期主要经营数据 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-089 湖南方盛制药股份有限公司 2024年前三季度经营数据公告 2、主营业务分类别情况中，"其他"主要是指除心脑血管疾病用药、抗感染用药、 儿童用药、妇科疾病用药、骨骼肌肉系统用药、呼吸系统用药之外的其他各类药品收入 及子公司的医疗服务收入、医药商业收入、技术服务收入； 3、主营业务分行业情况中，报告期内医药制造收入增长14.31%，主要系报告期内 核心产品尤其是慢病用药呈现稳健增长态势；医疗业务及其他收入较上年同期下降 27.59%，主要系重庆筱熊猫药业股份有限 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-084 湖南方盛制药股份有限公司 第五届董事会2024年第八次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）第五届董 事会 2024 年第八次临时会议于 2024 年 10 月 23 日下午 15:30 在 新厂办公大楼一楼会议室（一）以现场与通讯表决相结合的方式 召开。公司证券部已于 2024 年 10 月 19 日以电子邮件、微信、 电话等方式通知全体董事。本次会议由董事长周晓莉女士召集， 会议应出席董事 6 人，实际出席董事 6 人（独立董事高学敏先生 与杜守颖女士、袁雄先生以通讯方式参会）。本次会议参与表决 人数及召集、召开程序符合《公司法》和《公司章程》的有关规 定，会议合法有效。会议审议并通过了以下议案： 一、关于转让药品上市许可的议案 该议案表决情况：同意6票，反对0票，弃权0票，表 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-083 湖南方盛制药股份有限公司 关于召开2024年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 10 月 29 日(星期二)上午 10:00-11:00； 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/）； 会议召开方式：上证路演中心网络互动； 投资者可于 2024 年 10 月 22 日(星期二)至 10 月 28 日(星期一)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com、 603998@fangsheng.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖南方盛制药股份有限公司（以 ...